CancerX Selects First Ascent Biomedical into its 2025 Driving Innovation in Oncology Cohort
CancerX is a groundbreaking public-private partnership designed to accelerate innovation [...]
Clinical Results Published in Nature Medicine
This is the first time Nature Medicine published a Functional [...]
ASCO 2024 Clinical Results
Our study shows the technical feasibility of integrating functional precision [...]
Biomarker Development for Pharmaceutical Companies and Patients
Our studies demonstrate the potential for predictive and generative artificial [...]
ASCO2024 Press Release
First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric [...]
ASCO 2024 Abstract Presentations
First Ascent Biomedical Inc., a clinical-stage functional precision medicine company [...]
Functional Precision Medicine Leads to Better Cancer Treatments
Inside Precision Medicine April 18, 2024 IPM interviewed Dr. Diana [...]
New Study Shows Functional Precision Medicine Platform Identifies Effective Treatments for 83 Percent of Children with Difficult-to-Treat Cancers
Groundbreaking findings published in Nature Medicine shows improved outcomes [...]
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling-
Function Precision Medicine (FPM) and AI to provide new treatment [...]
IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma
Risk or presence of metastasis in medulloblastoma causes substantial treatment-related [...]